Ovid Therapeutics 2024年第四季度 GAAP每股收益 $-0.13 优于 $-0.16 的预期,每股销售额 $76K 低于 $189.286K 的预期

财报速递
11 Mar
Ovid Therapeutics(LENZ) 2024年第四季度的GAAP每股收益为$-0.13,优于预期的$-0.16,每股销售额为$76K,低于预期的$189.286K。

以上内容来自Benzinga Earnings专栏,原文如下:

Ovid Therapeutics Q4 2024 GAAP EPS $(0.13) Beats $(0.16) Estimate, Sales $76K Miss $189.286K Estimate

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10